Scynexis Inc (SCYX)

Scynexis Inc (SCYX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $37.7M; returns 1 day -0.7%, 1 week +3.1%, 1 year -38.6%.

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections. A key element of their strategy is the 'fungerp' platform. Their first drug from this platform, Ibrexafungerp, is licensed to GSK and is marketed as BREXAFEMME for vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC.

Groups SCYX belongs to

• Biotechnology
• Recent Reverse Splits
• Biopharmaceutical
• Pharmaceuticals
• Infectious Diseases
• Healthcare
• Life Sciences
• Commercial Stage Biotech
• Royalty Streams

SCYX financial model: income statement, cash flow and balance sheet